Patents

Search tools Text Classification Chemistry Measure Numbers Full documents Title Abstract Claims All Any Exact Not Add AND condition These CPCs and their children These exact CPCs Add AND condition
Exact Exact Batch Similar Substructure Substructure (SMARTS) Full documents Claims only Add AND condition Add AND condition
Application Numbers Publication Numbers Either Add AND condition

Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser

Classifications

C07D471/18 Bridged systems
View 6 more classifications

Landscapes

Organic Chemistry Chemical & Material Sciences
Show more

NO322016B1

Norway

Download PDF Find Prior Art Similar
Other languages
English
Norwegian
Inventor
Carmen Cuevas
Andres Francesch
Carolina Fernandez
Jose Luis Chicharro
Pilar Gallego
Maria Zarzuelo
Fernando De La Calle
Ignacio Manzanares
Marta Perez
Worldwide applications
2000 AR MY EP DE SI SK TR KR PT MX RU UA US AU CZ PL CN ES HU DK WO AT JP CA BR NZ 2001 CN WO SI CA ES AU CN BR CZ BR US WO SK CZ NO 2002 NO BG 2007 US CY
Application NO20015547A events
1999-05-14
Priority claimed from GBGB9911345.8A
1999-08-02
Priority claimed from GBGB9918178.6A
1999-10-06
Priority claimed from GBGB9923632.5A
2000-01-17
Priority claimed from GB0001063A
2001-11-13
Application filed by Pharma Mar Sa
2001-11-13
Publication of NO20015547D0
2002-01-14
Publication of NO20015547L
2006-08-07
Publication of NO322016B1
Info
Patent citations (19)
Cited by (44)
Legal events
Similar documents
Priority and Related Applications
External links
Espacenet
Global Dossier
Discuss

Patent Citations (19)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
FR2461995A1 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
JPS59225189A 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6054386A * 1983-09-02 1985-03-28 Yoshitomi Pharmaceut Ind Ltd サフラシン誘導体
JPS6084288A 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5256663A 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
FI885726A7 1986-06-09 1988-12-09 Univ Of Illinois Ekteinaskidiinit 729, 743, 745, 759A, 759B ja 770
US5089273A 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5478932A 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
SG50747A1 * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
US5721362A 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
SK285669B6 * 1998-04-06 2007-06-07 The Board Of Trustees Of The University Of Illinois Ekteinascidínová zlúčenina, farmaceutický prostriedok s jej obsahom a jej použitie
HUP0101960A3 1998-05-11 2003-03-28 Pharma Mar Sa Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them
US6124292A 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US6686470B2 2000-01-19 2004-02-03 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
ATE299146T1 2000-04-12 2005-07-15 Pharma Mar Sa Ecteinaschidin derivate mit antikrebs wirkung
MXPA02011319A 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
* Cited by examiner, † Cited by third party

Cited By (44)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
HUP0101960A3 1998-05-11 2003-03-28 Pharma Mar Sa Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them
MY164077A 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7919493B2 * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
ATE299146T1 * 2000-04-12 2005-07-15 Pharma Mar Sa Ecteinaschidin derivate mit antikrebs wirkung
JP4942900B2 * 2000-05-15 2012-05-30 ファルマ・マール・ソシエダード・アノニマ エクチナサイジン化合物の製造のための合成方法
US7420051B2 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
AU3956502A 2000-11-03 2002-05-27 Harvard College Saframycins, analogues and uses thereof
NZ525730A * 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
GB0117402D0 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
BR0213424A * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
GB0202544D0 * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0229793D0 * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7183054B2 2003-06-03 2007-02-27 President And Fellows Of Harvard College Assay for identifying biological targets of polynucleotide-binding compounds
GB0324201D0 * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
US20080255132A1 * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2583464A1 * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
CN101119750B * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
RU2382647C2 2004-10-29 2010-02-27 Фарма Мар С.А., Сосьедад Униперсональ Композиции, содержащие эктинэсайдин и дисахарид
GB0522082D0 * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
KR100712667B1 2006-04-11 2007-05-02 재단법인서울대학교산학협력재단 신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법
GB0708691D0 * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
US20090076017A1 * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
CA2703026A1 * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
WO2009138509A1 * 2008-05-16 2009-11-19 Pharma Mar, S.A. Multiple myeloma treatments
KR20110025178A * 2008-05-16 2011-03-09 파르마 마르 에스.에이. Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법
WO2011048210A1 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
CA2800097C * 2010-05-25 2019-01-08 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds and intermediates
TR201903859T4 2010-11-12 2019-04-22 Pharma Mar Sa Bir antitümör antibiyotik ile kombinasyon terapisi.
JOP20190254A1 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN107739387B * 2017-10-16 2020-01-03 上海皓元生物医药科技有限公司 一种制备曲贝替定的关键中间体化合物的方法
CN109912629B * 2017-12-13 2021-12-24 浙江中科创越药业有限公司 天然产物Trabectedin的制备
TWI824043B 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN111518110B * 2019-02-01 2023-11-03 博瑞生物医药（苏州）股份有限公司 一种海鞘素化合物及其中间体的制备方法
CN111620792B * 2019-02-28 2023-01-03 兰州大学 一种n,n-二取代氰基甲酰胺的合成方法
US20230027502A1 2019-11-21 2023-01-26 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CN116217584A * 2021-12-06 2023-06-06 南通诺泰生物医药技术有限公司 Et743及其中间体的光催化合成方法
WO2024155565A2 * 2023-01-17 2024-07-25 Yarrow Therapeutics, Inc. Ecteinascidin derivative antibody drug conjugates
WO2025077996A1 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
* Cited by examiner, † Cited by third party, ‡ Family to family citation

Similar Documents

Publication Publication Date Title
NO322016B1 2006-08-07 Anvendelse av utgangsmaterialer,fremgangsmate for hemisyntese av forbindelser og nye forbindelser
US7420051B2 2008-09-02 Synthetic process for the manufacture of an ecteinaschidin compound
EP1287004B1 2005-07-27 Synthetic process for the manufacture of an ecteinascidin compound
NO329561B1 2010-11-15 Forbindelser som er analoger av ET-743, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene til fremstilling av farmasoytiske preparater for anvendelse ved behandling av tumorer
BG106216A 2002-08-30 Полусинтетичен метод и нови съединения
HK1050193B 2006-03-03 Synthetic process for the manufacture of an ecteinascidin compound
NZ521808A 2004-07-30 Synthetic process for the manufacture of an ecteinaschidin compound
HK1053653A1 2003-10-31 Antitumoral analogs of et-743
HK1053653B 2005-06-03 Antitumoral analogs of et-743

Priority And Related Applications

Applications Claiming Priority (5)

Application Filing date Title
GBGB9911345.8A 1999-05-14
GBGB9918178.6A 1999-08-02 Synthetic methods
GBGB9923632.5A 1999-10-06 Hemisynthetic process towards ecteinascidin and phtalscidin compounds
GB0001063A 2000-01-17 Hemisynthetic process towards ecteinascidin and phtalascidin
PCT/GB2000/001852 2000-05-15 Hemisynthetic method and intermediates thereof

Legal Events

Date Code Title Description
2020-06-08 MK1K Patent expired

Concepts

machine-extracted
Download Filter table
Name Image Sections Count Query match
compounds title,claims,description 185 0.000
method title,claims,description 93 0.000
starting material title,claims,description 30 0.000
chemical reaction claims,description 93 0.000
hydroxymethylene group claims,description 70 0.000
1,4-benzoquinone claims,description 55 0.000
Phenol claims,description 44 0.000
hydroxy group claims,description 41 0.000
biosynthetic process claims,description 37 0.000
trabectedin claims,description 34 0.000
trabectedin claims,description 29 0.000
Saframycin claims,description 26 0.000
ketone group claims,description 24 0.000
acyl group claims,description 23 0.000
Ecteinascidin 743 claims,description 22 0.000
preparation method claims,description 21 0.000
cyano group claims,description 19 0.000
methoxy group claims,description 19 0.000
Safracin B claims,description 18 0.000
alkyl group claims,description 18 0.000
antibiotic em 5519 claims,description 18 0.000
hydrogen claims,description 18 0.000
aryl group claims,description 17 0.000
hydrogen claims,description 17 0.000
protecting group claims,description 17 0.000
Hydrogen claims,description 16 0.000
amino methylene group claims,description 16 0.000
synthesis reaction claims,description 16 0.000
carbon atom claims,description 15 0.000
process claims,description 15 0.000
chemical reaction reagent claims,description 11 0.000
Keto claims,description 10 0.000
ethyl group claims,description 10 0.000
substituent group claims,description 10 0.000
C([C@H](N1C)[C@@H]2C#N)C3=CC(C)=C(OC)C(O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O claims,description 9 0.000
renieramycin claims,description 9 0.000
alkoxy group claims,description 8 0.000
aryl alkyl group claims,description 8 0.000
atom claims,description 8 0.000
heterocyclic group claims,description 8 0.000
reduction claims,description 8 0.000
1,3-benzodioxol-4-ol claims,description 7 0.000
acetyl group claims,description 7 0.000
derivatisation claims,description 7 0.000
saframycin a claims,description 7 0.000
acylation claims,description 6 0.000
acylation reaction claims,description 6 0.000
methanide claims,description 6 0.000
primary amino group claims,description 6 0.000
Ecteinascidin 770 claims,description 5 0.000
Safracin A claims,description 5 0.000
safracin a claims,description 5 0.000
ac1l51xm claims,description 4 0.000
functional group claims,description 4 0.000
nucleophilic effect claims,description 4 0.000
Saframycin B claims,description 3 0.000
acetyloxy group claims,description 3 0.000
alkylene group claims,description 3 0.000
arginyl group claims,description 3 0.000
catalyst claims,description 3 0.000
cystyl group claims,description 3 0.000
decyano-saframycin a claims,description 3 0.000
displacement reaction claims,description 3 0.000
ecteinascidin 770 claims,description 3 0.000
glutamic acid group claims,description 3 0.000
glycyl group claims,description 3 0.000
halogen group claims,description 3 0.000
histidyl group claims,description 3 0.000
isoleucyl group claims,description 3 0.000
isovaleryl diethylamide claims,description 3 0.000
methane;palladium claims,description 3 0.000
nitro group claims,description 3 0.000
phenylalanyl group claims,description 3 0.000
prolyl group claims,description 3 0.000
saframycin b claims,description 3 0.000
saframycin r claims,description 3 0.000
substitution reaction claims,description 3 0.000
113036-78-5 claims,description 2 0.000
Renieramycin B claims,description 2 0.000
Renieramycin D claims,description 2 0.000
Renieramycin E claims,description 2 0.000
Saframycin C claims,description 2 0.000
Saframycin G claims,description 2 0.000
Saframycin Mx 1 claims,description 2 0.000
Saframycin Mx 2 claims,description 2 0.000
Saframycin Y3 claims,description 2 0.000
Saframycin YD-2 claims,description 2 0.000
acylamino group claims,description 2 0.000
acyloxy group claims,description 2 0.000
aryloxy group claims,description 2 0.000
carboxyalkyl group claims,description 2 0.000
halogen claims,description 2 0.000
heterocyclyloxy group claims,description 2 0.000
hydrophobic group claims,description 2 0.000
phenyl group claims,description 2 0.000
renieramycin C claims,description 2 0.000
saframycin c claims,description 2 0.000
saframycin d claims,description 2 0.000
saframycin f claims,description 2 0.000
saframycin g claims,description 2 0.000
saframycin h claims,description 2 0.000
saframycin y3 claims,description 2 0.000
saframycin-yd2 claims,description 2 0.000
alanyl group claims 3 0.000
1-amino-methylene claims 1 0.000
acid claims 1 0.000
butyloxycarbonyl group claims 1 0.000
glutaminyl group claims 1 0.000
hydroxy functional group claims 1 0.000
leucyl group claims 1 0.000
lysyl group claims 1 0.000
methionyl group claims 1 0.000
seryl group claims 1 0.000
thiols claims 1 0.000
threonyl group claims 1 0.000
tyrosyl group claims 1 0.000
valyl group claims 1 0.000
Show all concepts from the description section
Data provided by IFI CLAIMS Patent Services